Charles Payne here with an urgent opportunity:
The market just handed options traders a gift—and most people won't even notice it.
Volatility is spiking.
And when that happens, option premiums surge.
Options traders love it.
And so do I!
Because while everyone else is watching their portfolios swing wildly and losing sleep over whether to sell, options traders are cashing in on the chaos.
Higher volatility = fatter premiums = BIGGER paychecks.
You can collect more income in one volatile week than you'd normally make in a month of calm markets.
The opportunities right now are exceptional. But they won't last forever.
Volatility always settles down—and when it does, these premium levels disappear.
That’s why, in a few days, my team is hosting a free, live Power of Options Masterclass where we’re showing you exactly how to capitalize on these high-premium environments and what to do when the market gets cold.
You’ll learn how to collect significantly larger income checks. How to do it safely.
And how to take advantage before this window closes.
This is a live session. No charge.
The full details are on the next page…
So register here while the doors are open.
Charles Payne
Why Boston Scientific's Big Dip Could Be a Bigger Opportunity
Written by Nathan Reiff. Article Published: 3/24/2026.
Key Points
- Boston Scientific shares are down over 25% year-to-date after investors may have been disappointed by the company's 2026 sales guidance.
- Still, there are many positives that could entice investors keen to buy the dip, including strong free cash flow growth and the prospect of access to new markets with the impending completion of the Penumbra acquisition.
- A potential major catalyst for growth is the Champion trial, which could significantly increase the addressable patient pool of Boston Scientific's Watchman line.
- Special Report: Elon Musk already made me a "wealthy man"
Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) is off to a tough start — shares are down about 26% year-to-date (YTD) and nearly a third over the past year. Investors who examine the company's fundamentals will find some strong recent results, including adjusted earnings per share (EPS) of $0.80 for the last quarter, two cents above consensus expectations.
Indeed, a closer look at Boston Scientific's earnings shows the company is performing well—its electrophysiology (EP) segment, and Watchman products in particular, has grown rapidly and appears on track to continue delivering. The company is expected to report results from its Champion-AF trial by the end of March; positive data could meaningfully expand Watchman's addressable patient population. Investors may therefore be tempted to buy the dip in BSX stock, but it's important to remember why shares have fallen and what risks remain.
Is the Boston Scientific Dip Justified?
Why the Fed's new 24/7 banking system is a trap (Ad)
The Federal Reserve is selling banks their new FedNow system with one major promise: transfers will happen instantly, 24/7/365 with no more weekend or holiday delays—but when your money moves instantly through a centralized government hub, it can also be frozen instantly by automated algorithms inside the Fed's new network. Imagine it's 6:00 p.m. on a Friday when your account is instantly locked by a faceless government computer in Washington because an algorithm flagged a recent purchase or donation as suspicious, cutting you off from your own money until Monday morning or later with no way to pay for anything.
Get the 4 steps to Fed-proof your savings nowShares of BSX plunged after the February earnings release, despite revenue climbing about 16% year-over-year (YOY) and adjusted EPS beating expectations. Free cash flow also improved substantially, rising roughly 38% YOY to about $3.7 billion.
The selloff appears tied to the company's 2026 organic revenue guidance, which calls for YOY growth of 10% to 11% — notably slower than 2025's roughly 20% full-year growth. Part of the deceleration reflects the near-term impact of discontinuing certain products, including lines related to the Axios catheters, at the start of the year; management estimates this will shave about 150 basis points off early-2026 growth.
Still, much of Boston Scientific's business remains intact, growing, and efficient. Management expects another year of rising free cash flow — about $4.2 billion in 2026 — alongside continued operating-margin expansion and other improvements.
The Champion Trial Could Be a Catalyst for Reversal
The Champion trial, which compares the company's Watchman stroke-reduction implant to oral anticoagulation, could help reverse BSX's recent slide. Investors should watch these results closely: if outcomes are favorable, the addressable patient pool for Watchman could expand materially, potentially growing to as many as 20 million people.
Positive Champion data would have multi-year implications, allowing Boston Scientific to accelerate sales growth globally by identifying millions of additional potential patients.
Another growth driver could be the planned acquisition of neurovascular device maker Penumbra (NYSE: PEN). Penumbra's portfolio would give Boston Scientific an entry into the mechanical thrombectomy market, where it currently has no presence. The $14.5 billion deal is financed in part by a $6 billion term loan secured in late February. While the acquisition increases leverage, the company's rising free cash flow and strong underlying businesses may help alleviate near-term financial concerns.
Risks and Analyst Perspectives Are Worth Keeping in Mind
A negative Champion result would be a significant risk: it could curtail Watchman's sales trajectory and undermine Boston Scientific's broader revenue plans, making the company's 2026 guidance of 10%–11% growth harder to achieve.
Still, Wall Street remains largely bullish. Of 25 analyst ratings, 23 are Buys and two are Holds. Several firms, including Stifel Nicolaus, Jefferies, and Truist Financial, reissued Buy ratings in March, though some analysts have trimmed price targets while maintaining positive views.
The consensus price target of $106.27 sits more than 50% above BSX's current trading level, reflecting analysts' expectation of considerable upside if the company executes on its growth drivers and clinical milestones.
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments
Written by Nathan Reiff. Article Published: 3/12/2026.
Key Points
- Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk already made me a "wealthy man"
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to grow to $366 billion over the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, a number of promising treatments have shown strong potential—and with that comes the possibility of significant sales.
Two smaller biotech companies have seen notable share-price momentum thanks to their leading oncology medicines. Besides offering therapeutic potential, these drugs could help the firms move beyond penny-stock or otherwise unstable status and toward long-term profitability. In both cases, significant challenges remain, making these typical biotech investments high-risk but with the potential for outsized rewards.
Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle
Why the Fed's new 24/7 banking system is a trap (Ad)
The Federal Reserve is selling banks their new FedNow system with one major promise: transfers will happen instantly, 24/7/365 with no more weekend or holiday delays—but when your money moves instantly through a centralized government hub, it can also be frozen instantly by automated algorithms inside the Fed's new network. Imagine it's 6:00 p.m. on a Friday when your account is instantly locked by a faceless government computer in Washington because an algorithm flagged a recent purchase or donation as suspicious, cutting you off from your own money until Monday morning or later with no way to pay for anything.
Get the 4 steps to Fed-proof your savings nowIovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 fell about 1%. That added to IOVA's year-to-date performance, during which shares have more than doubled. Still, with a consensus price target of $8.88, Wall Street is signaling additional upside—about 71% from current levels.
The main catalyst for Iovance's move is Amtagvi, a T-cell immunotherapy for certain types of melanoma.
Amtagvi was approved in the U.S. for melanoma in 2024 and is gaining momentum, with rising sales and additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could reach more than $1 billion in U.S. peak sales.
Amtagvi's potential extends beyond melanoma: it received FDA Fast Track designation for non-small cell lung cancer and may be effective against other cancer types.
Iovance's outperformance was also supported by its Q4 2025 earnings report, issued in late February, where the company posted smaller-than-expected losses per share and $5 million in revenue. For the full year, revenue rose about 30% year over year.
Iovance is a small, roughly $2 billion biotech and a penny stock. Despite the rally, analysts remain cautious: about half of its dozen ratings are Hold or Sell. Risks include the company's complex manufacturing process for Amtagvi—the therapy is personalized, costly, and difficult to produce, which could limit profitability even as demand grows.
Massive Sales Growth for ImmunityBio's Bladder Cancer Drug
ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs Iovance's. IBRX shares are up nearly 300% in 2026 alone, and this could be just the beginning. Analysts have set a price target of $13.60, roughly 70% above the stock's current level even after the rally.
ImmunityBio's lead product is Anktiva, a treatment for certain bladder cancers. In February, shares spiked after the E.U. regulator granted the drug conditional marketing authorization, the latest in a string of approvals worldwide.
Anktiva helped drive revenue to $113 million last year—a roughly 700% year-over-year increase.
Like Amtagvi, Anktiva may have potential against other cancer types, and ImmunityBio is exploring additional indications.
Despite the surge over the last several quarters, IBRX shares remain speculative and risky.
IBRX reported a full-year net loss of $351 million for 2025 as R&D expenses remain high. Wall Street analysts are relatively more bullish than for Iovance: six of seven rate the stock a Buy or equivalent.
This email communication is a paid sponsorship provided by Paradigm Direct, a third-party advertiser of MarketBeat. Why did I receive this email message?.
If you have questions or concerns about your account, please don't hesitate to email our U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2026 MarketBeat Media, LLC.
345 N Reid Pl., Sixth Floor, Sioux Falls, SD 57103-7078. United States of America..